Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director | May 12, 2026 | May 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tonix Pharmaceuticals Holding Corp.
Report date May 12, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $13.28 · Expires 2036-05-12 | Direct | 22,700 |
Reported balance
After 2026-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-12 · Grant · Acquired 22,700 · Balance 22,700 F1: The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 14, 2026 21:45 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 22,700 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0001999371-26-010750 · treco-form4_051426.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,700 Underlying: Common Stock · 22,700 shares Expires 2036-05-12 F1 · price: The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan, and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders. Read SEC document |
| August 20, 2025 Filed Aug 20, 2025 20:15 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, par value $0.001 | 250 | $36.00 | $9,000.00 |
DisclosureSEC source: 0001999371-25-011754 · treco-form4_082025.xml · nonDerivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250 Read SEC document |
| May 13, 2025 Filed May 15, 2025 21:04 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $20.18 | $0.00 |
DisclosureSEC source: 0001999371-25-006255 · treco-form4.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-13 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended, and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2026 Annual Meeting of Stockholders. Read SEC document |
| February 05, 2025 Filed Feb 28, 2025 22:31 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | OtherCommon Stock, par value $0.001 | 0.02 | $0.30 | $0.01 |
DisclosureSEC source: 0001839882-25-012472 · treco-form4_022825.xml · nonDerivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Involuntary sale of fractional shares following a reverse stock split of the Issuer's common stock. Read SEC document |
| May 23, 2024 Filed May 24, 2024 21:10 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 104,621 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001999371-24-006625 · treco-form4.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,621 Underlying: Common Stock · 104,621 shares Expires 2034-05-23 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2025 Annual Meeting of Stockholders. Read SEC document |
| May 08, 2023 Filed May 10, 2023 21:01 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001387131-23-006320 · treco-form4_050823.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-05-08 F2 · shares: Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023. F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date or the Issuer's 2024 Annual Meeting of Stockholders. F2 · derivative.underlying_shares: Does not reflect a 1-for-6.25 reverse stock split of the Issuer's common stock effective May 10, 2023. Read SEC document |
| May 09, 2022 Filed May 11, 2022 21:38 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 2,131,500 | $0.00 Strike: $0.13 | $0.00 |
DisclosureSEC source: 0001387131-22-006014 · ownership.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,131,500 Underlying: Common Stock · 2,131,500 shares Expires 2032-05-09 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| May 10, 2021 Filed May 12, 2021 20:45 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 270,882 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001387131-21-005548 · ownership.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,882 Underlying: Common Stock · 270,882 shares Expires 2031-05-10 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 13:03 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, par value $0.001 | 5,500 | $0.89 | $4,895.00 |
DisclosureSEC source: 0001387131-20-008117 · ownership.xml · nonDerivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| August 14, 2020 Filed Aug 17, 2020 13:06 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | PurchaseCommon Stock, par value $0.001 | 4,500 | $1.06 | $4,770.00 |
DisclosureSEC source: 0001387131-20-007594 · treco-form4_081420.xml · nonDerivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Read SEC document |
| May 04, 2020 Filed May 6, 2020 22:33 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 112,500 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001387131-20-004493 · ownership.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2030-05-04 F1 · price: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan. Read SEC document |
| March 16, 2020 Filed Mar 18, 2020 20:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 6,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001387131-20-002994 · treco-form4_031620.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2030-03-16 F1 · price: The option was granted pursuant to the Issuer's 2020 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2020 Stock Incentive Plan. Read SEC document |
| May 06, 2019 Filed May 8, 2019 11:21 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 30,000 | Not disclosed Strike: $2.05 | Not disclosed |
DisclosureSEC source: 0001387131-19-003411 · ownership.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-05-06 F1 · price: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2019 Stock Incentive Plan. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:54 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 10,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0001387131-19-001333 · treco-form4_021419.xml · derivative · entry 1 Treco James · CIK 0001766070 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-02-14 F1 · derivative.exercise_date: The option was granted on February 14, 2019 pursuant to the Issuer's 2018 Equity Incentive Plan and vests on the date of the Issuer's 2019 annual meeting of shareholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.